Connor, Clark & Lunn Investment Management (CC&L)
ODT

Connor, Clark & Lunn Investment Management (CC&L)’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-124,179
Closed -$361K – 1257
2021
Q3 		$361K Buy
124,179
+4,170
+3% +$13.9K ﹤0.01% 836
2021
Q2 		$419K Buy
120,009
+72,138
+151% +$248K ﹤0.01% 818
2021
Q1 		$164K Buy
+47,871
New +$905K ﹤0.01% 931

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ODT Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 124,179 shares — an estimated $361K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ODT in Q1 2021 and held it in 3 quarters. The position peaked at $419K in Q2 2021. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 124,179 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $361K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Odonate Therapeutics, Inc. Common Stock position peaked at $419K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.